US-based biopharmaceutical firm Synchroneuron has dosed the first patient in a multi-centre, randomised, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy, safety and pharmacokinetic behaviour of orally administered SNC-102, a new formulation of acamprosate calcium, for the treatment of tardive dyskinesia (TD).

Around 90 patients will be enrolled in the trial, which will be carried out at 12 clinical sites to evaluate the clinical efficacy of SNC-102 tablets as measured by the Abnormal Involuntary Movement Scale (AIMS), the standard rating scale for measuring severity of involuntary movements in TD.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Using AIMS, the trial will assess the effectiveness of SNC-102 once daily (QD) or twice-daily (BID) versus placebo over a four week treatment period.

"There is a significant unmet medical need among patients who suffer from tardive dyskinesia, and SNC-102 has the potential to bring these patients much needed relief."

The trial will also characterise the pharmacokinetic profile in TD patients and its relationship to the clinical effects of the drug.

Synchroneuron chief executive officer William Kerns said: "Synchroneuron is committed to the development of what could be the first approved drug therapy for tardive dyskinesia, offering relief to patients who suffer the disabling and stigmatising effects of TD."

See Also:

Developed by Synchroneuron, SNC-102 is a formulation of acamprosate calcium, an FDA-approved drug for treating alcohol dependence, designed to improve the pharmacokinetic properties of acamprosate.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s Phase I trials have demonstrated that SNC-102 can produce sustained plasma levels of acamprosate that are expected to be efficacious for treating TD and potentially other neuropsychiatric disorders.

University of Toronto professor of Psychiatry Gary Remington said: "There is a significant unmet medical need among patients who suffer from tardive dyskinesia, and SNC-102 has the potential to bring these patients much needed relief from the often debilitating involuntary movements that characterise this disease."

The company said that participating sites in the trial include five academic centres of excellence in neurology and psychiatry.

The clinical sites include Atlanta Center for Medical Research; Baylor College of Medicine; Claghorn-Lesem Research Clinic; Northwestern University; Pacific Research Partners; Rush University Medical Center; Synergy Research; UCLA-Greater Los Angeles VA, and University of South Florida.